Short Interest in Knight Therapeutics Inc. (OTCMKTS:KHTRF) Declines By 35.2%

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 317,034 shares, a drop of 35.2% from the May 31st total of 489,147 shares. Based on an average trading volume of 24,638 shares, the short-interest ratio is presently 12.9 days.

Knight Therapeutics Stock Performance

KHTRF opened at $6.91 on Friday. Knight Therapeutics has a 12 month low of $4.07 and a 12 month high of $7.40. The stock’s 50 day moving average price is $6.24 and its 200 day moving average price is $5.19.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reissued an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy”.

About Knight Therapeutics

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.